Free Trial

Light Street Capital Management LLC Trims Stock Holdings in Cellebrite DI Ltd. (NASDAQ:CLBT)

Cellebrite DI logo with Business Services background

Light Street Capital Management LLC lessened its position in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 28.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 578,235 shares of the company's stock after selling 230,000 shares during the period. Cellebrite DI accounts for about 2.3% of Light Street Capital Management LLC's portfolio, making the stock its 17th biggest holding. Light Street Capital Management LLC owned about 0.28% of Cellebrite DI worth $12,739,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Barclays PLC increased its stake in shares of Cellebrite DI by 29.1% in the third quarter. Barclays PLC now owns 263,657 shares of the company's stock valued at $4,439,000 after buying an additional 59,395 shares during the period. Principal Financial Group Inc. bought a new stake in shares of Cellebrite DI in the 3rd quarter valued at about $23,402,000. JPMorgan Chase & Co. raised its holdings in Cellebrite DI by 21.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 427,655 shares of the company's stock worth $7,202,000 after purchasing an additional 75,092 shares during the last quarter. Jackson Square Capital LLC bought a new position in Cellebrite DI during the fourth quarter worth $1,596,000. Finally, SG Americas Securities LLC lifted its stake in shares of Cellebrite DI by 2,244.2% in the 4th quarter. SG Americas Securities LLC now owns 209,529 shares of the company's stock valued at $4,616,000 after purchasing an additional 200,591 shares during the period. 45.88% of the stock is currently owned by institutional investors.

Cellebrite DI Stock Performance

Shares of Cellebrite DI stock traded up $0.14 during trading hours on Friday, reaching $17.41. The company's stock had a trading volume of 1,845,732 shares, compared to its average volume of 1,457,594. Cellebrite DI Ltd. has a one year low of $10.25 and a one year high of $26.30. The company has a market capitalization of $4.17 billion, a P/E ratio of -12.53, a P/E/G ratio of 4.27 and a beta of 1.44. The stock's fifty day simple moving average is $19.02 and its two-hundred day simple moving average is $20.23.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The company reported $0.07 earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. As a group, research analysts forecast that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Needham & Company LLC cut their target price on shares of Cellebrite DI from $28.00 to $24.00 and set a "buy" rating on the stock in a research note on Wednesday. Lake Street Capital increased their target price on shares of Cellebrite DI from $17.00 to $26.00 and gave the stock a "buy" rating in a research note on Friday, February 14th. Finally, JPMorgan Chase & Co. cut their target price on shares of Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating on the stock in a research note on Monday, May 12th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of "Buy" and an average price target of $22.43.

Get Our Latest Analysis on CLBT

About Cellebrite DI

(Free Report)

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.

Recommended Stories

Institutional Ownership by Quarter for Cellebrite DI (NASDAQ:CLBT)

Should You Invest $1,000 in Cellebrite DI Right Now?

Before you consider Cellebrite DI, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.

While Cellebrite DI currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock
The Hottest AI Stock You Haven’t Bought Yet

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines